Avoiding 20% In Investment Waste During Launch

It’s a long-standing perception that pharma overspends during launch, but we did not have the data or methodology to understand or validate this notion. Until now.

The research team quantified the cost of a traditional launch by analyzing real-world examples. After examining a cohort of 75 companies with launches completed between 2014 and 2020, 10 launches with rich commercialization data were analyzed. After comparing that data to the cost efficiencies that can be realized through adopting a fully outsourced commercial model typically offered by contract commercial organizations — a new option that emerged in the past three years — the results were astounding.